Evotec SE Successfully Placed €116.1 Million Convertible Bonds
Evotec Announces Nomination of First Preclinical Development Candidate in Dermatology Collaboration with Almirall
Evotec Receives Grants to Advance Tuberculosis Treatment
Evotec Announces New Nomination to Board of Directors
Evotec SE to Announce First Quarter 2026 Results on May 6, 2026
Evotec Announces Chief Financial Officer Transition
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
Evotec SE (EVO) Q4 2025 Earnings Call Transcript
Evotec vows to further engage with investor MAK, who demanded change
Evotec Nominates Dieter Weinand as Supervisory Board Chairman
Evotec SE to Announce Fourth Quarter and Full-Year 2025 Results on April 8, 2026
Evotec Appoints Dr. Ashiq H. Khan as Chief Commercial Officer
Evotec (EVO) to Release Quarterly Earnings on Wednesday
Just - Evotec Biologics Enters Project Agreement with BARDA to Optimize Biomanufacturing of Antibodies Against Ebola and Related Viruses
Evotec Receives $10 M Milestone from Bristol Myers Squibb Protein Degradation Collaboration for Clinical Study Initiation
Evotec Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Evotec SE (EVO) Discusses Horizon Initiative as Next Phase in Strategic Transformation for Operational Excellence and Growth Transcript
Moving iMage Transforms Eight Screen Santa Fe Theater Complex for EVO Entertainment with Cutting-Edge Laser Projection and Digital Sound Systems, including an EVX Enhanced Viewing Experience Auditorium
FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis
Just - Evotec Biologics Receives Grant for AI-Driven Optimization of Monoclonal Antibody Developability for Affordable Access
Evotec Appoints Dr. Sarah Fakih as EVP, Head of Global Communications and Investor Relations
Evotec Closes Sale of Just - Evotec Biologics' Toulouse Site to Sandoz
Evotec-Partner Bayer Starts Phase 2 Study for Treatment of Patients with Alport Syndrome
Digital Ally Adds New In-Car Camera Solution EVO-CORE to its Ecosystem of Video Products
Evotec Receives Milestone Payment from Bristol Myers Squibb Following IND Acceptance in Strategic Protein Degradation Partnership
Evotec SE (EVO) Q3 2025 Earnings Call Transcript
Evotec SE Reports 9M 2025 Results: Continued Strong Execution on Strategic Priorities
In A Landmark Industry Transaction, Evotec Signs Agreement With Sandoz, Resulting In Payments Potentially Over US $650 M Plus Royalties
Evotec SE to Announce Results for The First Nine Months 2025 on 05 November 2025
Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
iA Financial Group Propels Advisors' Digital Experience to New Heights With the Launch of the Web Version of EVO Insurance
Evotec SE (EVO) Q2 2025 Earnings Call Transcript
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Evotec SE to announce first half-year results 2025 on 13 August 2025
Evotec SE and Sandoz AG Planning Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec, Webull And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
Evotec SE Adjusts Revenue Guidance while Confirming Profit Guidance
Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury
Evotec Receives $ 2.5 m Grant to Generate Next Generation Tuberculosis Treatments
Evotec SE (EVO) Q1 2025 Earnings Call Transcript
Evotec SE Reports Q1 2025 results: Paving the Way for 2025 Growth in Soft Market Environment
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb
Evotec SE (EVO) Q4 2024 Earnings Call Transcript
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb